Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 3, 349-356 doi:10.3324/haematol.10649
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ocaña, E.
Right arrow Articles by Brieva, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ocaña, E.
Right arrow Articles by Brieva, J. A.

Chronic Lymphocytic Leukemia

The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells

Esther Ocaña, Luis Delgado-Pérez, Antonio Campos-Caro, Juan Muñóz, Antonio Paz, Rafael Franco, José A. Brieva

Servicio de Inmunología and Unidad de Investigación (EO, LD-P, AC-C, JAB); Servicio de Hematología, Hospital Universitario Puerta del Mar, Cádiz, Spain (JM); Servicio de Hematología, Hospital Universitario de Puerto Real, Cádiz, Spain (AP); Servicio de Hematología, Hospital Punta Europa, Algeciras, Cádiz, Spain (RF)

Correspondence: José A. Brieva, Servicio de Inmunología, Hospital Universitario Puerta del Mar, Avenida Ana de Viya 21, 11009 Cádiz, Spain. E mail: josea.brieva.sspa{at}juntadeandalucia.es

Background and Objectives: Chemokine receptors are involved in tumor progression and several of these receptors, including CXCR3, are expressed by chronic lymphocytic leukemia (CLL) B cells. This study was aimed to examine a possible relationship between CXCR3 expression in CLL and the clinical evolution of the disease.

Design and Methods: Using flow activated cell sorting (FACS), we analyzed the level of expression of CXCR3 on blood CLL B cells from 76 consecutive patients. The results were correlated with CD38 expression, IgVH gene status and clinical outcome.

Results: CXCR3, measured as mean fluorescence intensity (MFI), was unimodally expressed by blood tumor cells at various levels (range, 3.5 to 232.3) but levels within individual patients were remarkably stable over time. Low CXCR3 expression by CLL B cells was strongly associated with Rai disease stages III and IV (p<0.0001) and a pattern of diffuse tumor infiltration of the bone marrow (p<0.0001). In the 28 cases available for genetic studies, low CXCR3 expression also showed good concordance with tumor unmutated IgVH gene status (p<0.04), and tended to correlate with high CD38 expression (p<0.06). Patients with low CXCR3 expression (MFI ≤15) had a shorter survival (p<0.0001) and, in multivariate analysis, low CXCR3 expression (MFI ≤15) was an independent predictor of poor outcome (hazard ratio 24.5; p<0.01).

Interpretation and Conclusions: CXCR3 expression by CLL B cells appears to be stable within individual patients. Tests to assay this chemokine receptor are cheap and easy to perform and the results could be of prognostic value in CLL.

Key words: chronic lymphocytic leukemia, CXCR3 expression by CLL B cells, prognostic factors.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.